Metronidazole DC Granules are pharmaceutical formulation granules containing Metronidazole in a controlled granular format intended for direct-compression applications. Metronidazole is a synthetic nitroimidazole active pharmaceutical ingredient used in pharmaceutical formulations. The USP-NF monograph identifies Metronidazole with the molecular formula C6H9N3O3, molecular weight 171.15 g/mol, and CAS Number 443-48-1. The USP definition specifies 99.0% to 101.0% Metronidazole, calculated on the dried basis.
The DC designation refers to Direct Compression. Direct compression requires suitable material properties because particle-size distribution, flowability, density, compressibility, compactability and content uniformity can influence processing and finished-tablet quality. Research involving Metronidazole formulations has specifically investigated direct compression and the effect of material and excipient characteristics on tablet performance.
Metronidazole DC Granules are a granulated pharmaceutical formulation containing Metronidazole together with selected excipients. The granular format is intended to provide controlled physical characteristics for handling, blending and compression.
The finished granules should be distinguished from Metronidazole API. The API is a chemically defined substance, whereas the finished DC granules are a formulation system containing the active ingredient and other formulation components.
The physical properties of the finished granules depend on the API characteristics, excipient selection, granulation or particle-engineering process, particle-size distribution, moisture level and manufacturing conditions.
Metronidazole has the molecular formula C6H9N3O3 and molecular weight 171.15 g/mol. The USP-NF monograph lists CAS Number 443-48-1 and specifies 99.0% to 101.0% content on the dried basis for the API substance.
For finished Metronidazole DC Granules, the API assay should be determined using the validated analytical method applicable to the finished formulation. The API monograph requirement should not automatically be treated as the finished-granule assay unless the approved specification uses the same analytical basis.
Direct compression is a tablet manufacturing process in which a suitable formulation blend is compressed directly into tablets. The suitability of a formulation for this process depends on the physical properties of the formulation materials.
Research has demonstrated direct-compression preparation of Metronidazole-containing tablets and evaluated physicochemical and release characteristics.
Another study used Metronidazole as a model active ingredient to investigate direct-compression excipient performance, highlighting the importance of flow and compression behavior.
For Metronidazole DC Granules, important physical characteristics may include:
The actual acceptance criteria should be established from the approved finished-product specification.
Particle-size distribution is an important quality attribute for Metronidazole DC Granules because particle size can influence flow, packing, blend uniformity and compression behavior.
D10, D50 and D90 may be used to characterize the finished granules when these parameters are included in the product specification.
Research on Metronidazole granules has demonstrated that the physical properties of the starting API can influence granule characteristics, including porosity, friability, loss on drying and flowability, and can subsequently affect tabletability and compressibility.
Therefore, particle-size limits should be based on actual manufacturing and analytical data rather than assigned as universal values.
Consistent flow is important for the transfer, blending and feeding of pharmaceutical granular materials.
Metronidazole DC Granules may be evaluated using:
These measurements can help characterize the physical handling properties of the finished formulation.
Direct-compression research has shown that excipient selection and particle characteristics can affect flow and tabletability.
Compressibility and compactability are important considerations for a formulation intended for direct compression.
Compressibility describes the response of the granular material to applied pressure, while compactability describes the ability of the material to form a mechanically strong compact.
During development of Metronidazole DC Granules, formulation developers may evaluate:
These properties are dependent on the complete formulation and manufacturing process.
Research has specifically examined Metronidazole powder and excipient combinations in relation to compression behavior and tablet capping.
Content uniformity is an important quality attribute for finished formulations containing Metronidazole. Uniform distribution of the active ingredient throughout the granulated formulation supports consistent dosage-unit manufacturing.
The finished product may be evaluated using validated sampling and analytical procedures.
The acceptance criteria should correspond to the approved product specification and applicable quality requirements.
The dissolution behavior of Metronidazole formulations depends on API characteristics, particle size, excipient composition, granule structure, compression conditions and formulation design.
Direct-compression Metronidazole formulations have been evaluated for dissolution and other tablet-performance characteristics.
Metronidazole can also be incorporated into modified-release formulations. Research has demonstrated that polymer composition can significantly modify its release profile.
However, DC does not automatically mean immediate release or sustained release. For a product specifically named Metronidazole DC Granules, the page should focus on the direct-compression granular format unless the actual product specification establishes an additional release characteristic.
Specific dissolution percentages or time points should only be published when supported by the validated finished-product specification.
Moisture content can influence the physical characteristics of pharmaceutical granules, including flow, packing and compression behavior.
For Metronidazole DC Granules, moisture should be controlled according to the approved product specification and supported by stability studies.
Research on Metronidazole granules has included loss on drying among the evaluated granule properties, demonstrating the relevance of moisture-related characteristics during granule development.
Packaging and storage conditions should be established according to validated stability data and the characteristics of the finished formulation.
Metronidazole DC Granules may be evaluated for oral solid dosage formulations requiring a controlled granular format for direct compression.
Potential formulation-development applications include:
The final formulation composition and processing conditions should be established through formulation development and validation.
Quality control of Metronidazole DC Granules should address chemical identity, assay, purity and physical processing characteristics.
Potential quality attributes include:
USP-NF specifies Metronidazole at 99.0% to 101.0% on the dried basis for the API substance.
This API requirement should be distinguished from the finished-product specification for Metronidazole DC Granules.
Development of Metronidazole DC Granules can involve systematic evaluation of the active ingredient, excipients and physical properties of the granular formulation.
Important development studies may include:
The SeDeM approach has also been described as a tool for assessing material properties and determining suitability for direct-compression formulation development.
Metronidazole DC Granules may be considered for:
The final application and performance should be established through product-specific formulation development and validation.
| Parameter | Specification |
|---|---|
| Appearance | White to off-white granules |